HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Business Round-Up: Galenica Acquires Spagyros, Karo Offloads OTCs, And Ceres Gets New Owners

Executive Summary

The latest European business news: Galenica strengthens its porfolio in Switzerland with Spagyros; Sweden's Karo offloads OTCs to Evolan; and Ceres Pharma sold to French private-equity firm.

You may also be interested in...



Ceres Pharma Enhances Supplements Portfolio With Deals In Belgium And Romania

Consumer health player Ceres will grow its European dietary supplements offering with the acquisitions of Belgium's Labophar and Romania's Dacia Plant.

Omicron And Acquisitions Push Up Galenica's Swiss OTC Sales By A Third

Galenica's Verfora substantially outpaced the 6.4% growth rate of the Swiss consumer health market in the first half, posting sales up by a third thanks to a combination of acquisitions and increased demand for cold & flu products due to the spread of the COVID-19 Omicron variant.

Boiron Partners With Galenica's Verfora In Switzerland

France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel